BRIVIACT Drug Patent Profile

Which patents cover Briviact, and what generic alternatives are available?

Briviact is a drug marketed by Ucb Inc and is included in three NDAs. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and seventy-three patent family members in forty-five countries.

The generic ingredient in BRIVIACT is brivaracetam. Six suppliers are listed for this compound. Additional details are available on the brivaracetam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Briviact

A generic version of BRIVIACT was approved as brivaracetam by SUNSHINE on June 9^th, 2022.

Summary for BRIVIACT

International Patents:	173
US Patents:	2
Applicants:	1
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BRIVIACT

Paragraph IV (Patent) Challenges for BRIVIACT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BRIVIACT	Tablets	brivaracetam	10 mg, 25 mg, 50 mg, 75 mg and 100 mg	205836	7	2020-05-12
BRIVIACT	Injection	brivaracetam	50 mg/5 mL	205837	2	2020-05-12
BRIVIACT	Oral Solution	brivaracetam	10 mg/mL	205838	1	2020-05-12

US Patents and Regulatory Information for BRIVIACT

BRIVIACT is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	BRIVIACT	brivaracetam	SOLUTION;INTRAVENOUS	205837-001	May 12, 2016		RX	Yes	Yes	6,911,461		Y	Y
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-002	May 12, 2016	AB	RX	Yes	No	10,729,653		Y
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-001	May 12, 2016	AB	RX	Yes	No	6,911,461		Y	Y

International Patents for BRIVIACT

When does loss-of-exclusivity occur for BRIVIACT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Mexico

Montenegro

Poland

Portugal

San Marino

Serbia

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BRIVIACT around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2005125645
Denmark	1447399
Yugoslavia	63102

Supplementary Protection Certificates for BRIVIACT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1452524	CR 2016 00013	Denmark		PRODUCT NAME: BRIVARACETAM; REG. NO/DATE: EU/1/15/1073/001-022 20160118
1452524	132016000045699	Italy		PRODUCT NAME: BRIVARACETAM(BRIVIACT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1073, 20160118
1452524	16C1001	France		PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 20160118

Investment Scenario, Market Dynamics, and Financial Trajectory for BRIVIACT

Last updated: February 3, 2026

Summary

BRIVIACT (generic name: brivaracetam) is an antiepileptic drug marketed primarily for adjunctive therapy in partial-onset seizures. Since its approval, the drug has exhibited steady growth driven by epilepsy prevalence, expanding indications, and evolving market trends favoring newer, targeted therapeutics. This report analyzes the current market landscape, competitive positioning, growth drivers, and financial outlook for BRIVIACT, focusing on the key factors influencing investment decisions.

---

1. Market Overview and Disease Epidemiology

Parameter	Data/Insight
Global Epilepsy Prevalence (2022)	50 million people; roughly 0.6% of the world population [1]
Partial-Onset Seizures Prevalence	Estimated at 20-40% of epilepsy cases, affecting approximately 10 million globally [2]
Market Demographics	Higher prevalence in adolescents and adults; increased prevalence in aging populations
Unmet Medical Needs	Better tolerability, fewer drug interactions, improved seizure control

Source: WHO (2022), Epilepsy Foundation [1][2]

---

2. Product Profile and Positioning of BRIVIACT

Attribute	Details
Generic Name	Brivaracetam
Brand Name	BRIVIACT
Therapeutic Area	Antiepileptic/Neurology
Approved Indications	Adjunctive treatment for partial-onset seizures in epilepsy patients (FDA, EMA)
Formulation(s)	Oral tablets, injectable formulations
Pharmacodynamics	High affinity for synaptic vesicle protein 2A (SV2A); enhances seizure threshold
MAC/Marketed by	UCB Pharma (original developer), licensed to multiple generics and regional players

Key Competitive Advantages

• Increased selectivity and tolerability over older agents like levetiracetam
• Favorable pharmacokinetics (fast absorption, minimal interactions)
• Potential extending indications to other seizure types

---

3. Market Dynamics

3.1 Competitive Landscape

Competitors	Key Attributes	Market Share (2022)	Notes
Levetiracetam (Keppra)	Market leader, broad indications	~40%	Highly prescribed, but with tolerability issues for some patients
Lamotrigine	Widely used, broad spectrum	~20%	Has multiple formulations, generic presence
Eslicarbazepine (Zebinix)	Similar indications, newer agent	~5%	Expanding into partial-onset seizure market
Brivaracetam (BRIVIACT)	Premium positioning, targeted efficacy	Growing	Steady growth in developed markets, expanding into emerging markets

3.2 Market Growth Drivers

Driver	Impact
Increasing prevalence of epilepsy	Expanded patient base boosting drug demand
Adoption of newer AEDs	Shift from older drugs to better-tolerated agents like BRIVIACT
Regulatory approvals of novel indications	Extending market applicability
Rising healthcare expenditure in neurology	Funding for epilepsy management, encourages drug adoption

3.3 Pricing and Reimbursement Landscape

Aspect	Details
Pricing Strategy	Premium pricing for branded BRIVIACT; generics rapidly entering markets
Reimbursement Policies	Varies by country; insurance coverage favors newer agents in some markets
Cost-Effectiveness Studies	Demonstrated improved tolerability linked to better adherence

---

4. Financial Trajectory and Investment Outlook

4.1 Revenue Forecasts and Growth Projections

Year	Estimated Global Sales (USD Million)	Growth Rate	Assumptions/Comments
2023	~950	10%	Increased adoption due to expanded indications
2024	~1,045	10%	Entry into additional markets (e.g., Asia, Latin America)
2025	~1,150	10%	Launch of extended indications and formulations
2026	~1,265	10%	Market saturation begins in mature regions

Sources: Company Reports, EvaluatePharma, 2022 estimates

4.2 Cost Structure and Margin Analysis

Parameter	Impact
R&D Expenses	Focus on new indication development; moderate due to established therapeutic mechanism
Manufacturing Costs	Stabilizing with generic competition, economies of scale
Marketing & Sales	Significant investment in key markets to expand penetration
Profit Margins	Expected to stabilize around 25% in mature markets after initial growth phases

4.3 Risks and Challenges

Risk Factor	Impact
Patent Expiry	Typically around 2030-2035; potential generic erosion
Market Penetration Barriers	Regulatory delays, limited access in emerging markets
Competitive Innovations	Development of novel agents or biosimilars
Pricing Pressure	Increasing generic competition influences margins

---

5. Market Expansion and Development Strategies

Strategy	Intended Outcome
Indication Expansion	Broaden use to other seizure types or neurological disorders
Geographic Expansion	Increase presence in Asia-Pacific, Latin America, Africa
Formulation Innovation	Develop extended-release or IV formulations
Strategic Alliances and Licensing	Accelerate market entry and share commercialization costs

---

6. Comparative Analysis with Key Antiepileptic Drugs

Attribute	BRIVIACT	Levetiracetam	Lamotrigine	Eslicarbazepine
Market Share (2022)	Growing	~40%	~20%	~5%
Tolerability Profile	Favorable	Moderate	Good	Good
Indication Breadth	Partial seizures	Broad spectrum	Broad spectrum	Partial seizures
Patent Status	Active, till late 2020s	Patented, expired	Patented, expired	Patented, expiring soon
Pricing (Premium/Generic)	Premium/Generic	Generics widely available	Generics available	Generics available

---

7. Regulatory and Policy Environment

Region	Regulatory Status	Key Policies
US (FDA)	Approved; patents till ~2030	Favorability towards innovative epilepsy agents
EU (EMA)	Approved; patent protection till late 2020s	Emphasis on tolerability and new indications
Japan	Approved; pathway for new therapies	Growing acceptance of targeted neurology drugs
China, India	Regulatory pathways evolving, generics prevalent	Market access influenced by pricing and local policies

---

8. Investment Considerations

Aspect	Evaluation
Market Growth Potential	Robust, supported by rising epilepsy burden and new indications
Competitive Positioning	Strong, especially given favorable tolerability profile
Patent Landscape	Patent expiry risk in late 2020s; strategic timing of sustained innovation crucial
Pricing and Reimbursement	Premium pricing supports margins; increasing generic competition necessitates innovation
Entry Barriers	Moderate; regulatory and market entry hurdles vary by region

---

Key Takeaways

• Market Opportunity: The global epilepsy market exceeds USD 4 billion annually, with partial-onset seizures forming a significant segment, offering sustained growth avenues for BRIVIACT.

• Growth Drivers: Increasing prevalence, expanding indications, and favorable tolerability position BRIVIACT for steady growth, projected around 10% annually through 2025.

• Competitive Edge: BRIVIACT benefits from high selectivity, improved side-effect profile, and targeted marketing strategies. Patent protections jut into the late 2020s, after which generic competition will intensify.

• Risks & Challenges: Patent expiration, commoditization of generics, regulatory delays, and pricing pressures could impact margins. Diversification of indications and geographic expansion are critical to mitigating these risks.

• Investment Outlook: Favorable long-term; early to mid-2020s represent an optimal window for growth, contingent on successful indication extension and market penetration.

---

FAQs

Q1: What is the projected patent expiry for BRIVIACT, and how will it affect the market?
A1: BRIVIACT's primary patents are expected to expire around 2030-2035. Post-expiry, generic versions will likely erode branded sales unless new indications or formulations are introduced. Strategic patent extensions or formulation innovations could mitigate this impact.

Q2: How does BRIVIACT compare to older antiepileptic drugs in terms of safety?
A2: BRIVIACT generally demonstrates better tolerability and fewer adverse effects, such as behavioral issues, compared to older agents like levetiracetam, supporting improved patient adherence and potential market share gains.

Q3: What are the key geographic markets for the expansion of BRIVIACT?
A3: The United States and Europe are mature markets. Growth opportunities exist in Asia-Pacific, Latin America, and Africa, driven by increasing epilepsy prevalence and improving healthcare infrastructure.

Q4: Are there ongoing clinical trials expanding BRIVIACT’s indications?
A4: Yes, ongoing studies are evaluating BRIVIACT for generalized seizures, Lennox-Gastaut syndrome, and other neurological conditions, which could significantly expand its market if successful.

Q5: What strategic steps could maximize BRIVIACT’s value in the coming years?
A5: Key strategies include indication expansion, formulation innovation (e.g., extended-release tablets), geographic diversification, and securing regulatory approvals for new uses to extend product lifecycle and revenue streams.

---

References

[1] World Health Organization. (2022). Epilepsy: Fact Sheet.
[2] Epilepsy Foundation. (2021). Epidemiology and Seizure Types.
[3] EvaluatePharma. (2022). Global Sales Data for Antiepileptic Drugs.
[4] UCB Pharma official reports. (2022). BRIVIACT Market Performance and Pipeline Updates.